FindTrial
Sign In

An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme.

An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001664-50-IT
Enrollment
Unknown
Registered
2005-06-15
Start date
2005-02-04
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or progressive glioblastoma multiforme after radiotherapy and adjuvant chemiotherapy. Level: PT Classification code 10018337

Interventions

Trade Name: Muphoran Product Name: NA Product Code: NA Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Fotemustine CAS Number: 92118-27-9 Concentration unit: mg

Sponsors

ITALFARMACO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026